Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) is a clinical stage pharmaceutical company focused on the development and commercialization of new therapeutics to treat rare, life-threatening inflammatory-fibrotic diseases with clear unmet medical needs. The company’s leading product candidate, Resunab, is a first-in-class oral anti-inflammatory drug currently scheduled to commence Phase II clinical trials for the treatment of cystic fibrosis and diffuse scleroderma later this year pending FDA approval of IND. For more information, visit the company’s website at www.corbuspharma.com.

Noble Financial Capital Markets, an equity research driven, full-service, investment banking boutique, is hosting its tenth annual equity conference in Sandpiper Bay, FL. Attended by institutional investors from across North America, the event features more than 140 public company executive teams from a diverse range of industries. For more information, visit www.noble.missionir.com.